nodes	percent_of_prediction	percent_of_DWPC	metapath
Ceftriaxone—SLC22A11—Conjugated Estrogens—prostate cancer	0.119	0.192	CbGbCtD
Ceftriaxone—SLC22A11—Estradiol—prostate cancer	0.104	0.169	CbGbCtD
Ceftriaxone—ALB—Abiraterone—prostate cancer	0.0867	0.14	CbGbCtD
Ceftriaxone—SLC22A8—Conjugated Estrogens—prostate cancer	0.0691	0.112	CbGbCtD
Ceftriaxone—ALB—Estrone—prostate cancer	0.0626	0.102	CbGbCtD
Ceftriaxone—SLC22A8—Estradiol—prostate cancer	0.0606	0.0983	CbGbCtD
Ceftriaxone—SLC22A6—Conjugated Estrogens—prostate cancer	0.0481	0.078	CbGbCtD
Ceftriaxone—ALB—Estradiol—prostate cancer	0.036	0.0583	CbGbCtD
Ceftriaxone—ALB—Prednisone—prostate cancer	0.0309	0.0501	CbGbCtD
Ceftriaxone—SLC22A8—urine—prostate cancer	0.00588	0.145	CbGeAlD
Ceftriaxone—GLUL—prostate gland—prostate cancer	0.00355	0.0875	CbGeAlD
Ceftriaxone—GLUL—epithelium—prostate cancer	0.00261	0.0643	CbGeAlD
Ceftriaxone—SLC22A11—renal system—prostate cancer	0.00255	0.0629	CbGeAlD
Ceftriaxone—GLUL—renal system—prostate cancer	0.00242	0.0597	CbGeAlD
Ceftriaxone—GLUL—urethra—prostate cancer	0.00238	0.0586	CbGeAlD
Ceftriaxone—SLC15A1—epithelium—prostate cancer	0.00215	0.0532	CbGeAlD
Ceftriaxone—SLC22A8—prostate gland—prostate cancer	0.00211	0.0521	CbGeAlD
Ceftriaxone—SLC15A1—renal system—prostate cancer	0.002	0.0493	CbGeAlD
Ceftriaxone—SLC15A2—prostate gland—prostate cancer	0.00183	0.0452	CbGeAlD
Ceftriaxone—GLUL—bone marrow—prostate cancer	0.00183	0.0451	CbGeAlD
Ceftriaxone—GLUL—testis—prostate cancer	0.00156	0.0386	CbGeAlD
Ceftriaxone—SLC15A2—seminal vesicle—prostate cancer	0.00155	0.0383	CbGeAlD
Ceftriaxone—SLC22A8—renal system—prostate cancer	0.00144	0.0355	CbGeAlD
Ceftriaxone—SLC15A2—renal system—prostate cancer	0.00125	0.0308	CbGeAlD
Ceftriaxone—SLC15A2—urethra—prostate cancer	0.00123	0.0303	CbGeAlD
Ceftriaxone—GLUL—lymph node—prostate cancer	0.00113	0.028	CbGeAlD
Ceftriaxone—ALB—testis—prostate cancer	0.000968	0.0239	CbGeAlD
Ceftriaxone—Cefazolin—PON1—prostate cancer	0.000844	0.71	CrCbGaD
Ceftriaxone—SLC15A2—testis—prostate cancer	0.000808	0.0199	CbGeAlD
Ceftriaxone—ALB—lymph node—prostate cancer	0.000701	0.0173	CbGeAlD
Ceftriaxone—SLC15A2—lymph node—prostate cancer	0.000585	0.0144	CbGeAlD
Ceftriaxone—Cefdinir—MPO—prostate cancer	0.000345	0.29	CrCbGaD
Ceftriaxone—Blood creatinine increased—Epirubicin—prostate cancer	0.000155	0.000642	CcSEcCtD
Ceftriaxone—Dizziness—Conjugated Estrogens—prostate cancer	0.000154	0.000641	CcSEcCtD
Ceftriaxone—Feeling abnormal—Estradiol—prostate cancer	0.000154	0.000639	CcSEcCtD
Ceftriaxone—Convulsion—Etoposide—prostate cancer	0.000154	0.000638	CcSEcCtD
Ceftriaxone—Dyspepsia—Mitoxantrone—prostate cancer	0.000153	0.000636	CcSEcCtD
Ceftriaxone—Gastrointestinal pain—Estradiol—prostate cancer	0.000153	0.000634	CcSEcCtD
Ceftriaxone—Flushing—Capecitabine—prostate cancer	0.000152	0.000632	CcSEcCtD
Ceftriaxone—Chills—Docetaxel—prostate cancer	0.000152	0.000631	CcSEcCtD
Ceftriaxone—Abdominal pain upper—Epirubicin—prostate cancer	0.000151	0.000626	CcSEcCtD
Ceftriaxone—Vomiting—Goserelin—prostate cancer	0.00015	0.000622	CcSEcCtD
Ceftriaxone—Discomfort—Etoposide—prostate cancer	0.000149	0.00062	CcSEcCtD
Ceftriaxone—Pain—Mitoxantrone—prostate cancer	0.000149	0.000618	CcSEcCtD
Ceftriaxone—Aspartate aminotransferase increased—Epirubicin—prostate cancer	0.000149	0.000618	CcSEcCtD
Ceftriaxone—Toxic epidermal necrolysis—Epirubicin—prostate cancer	0.000149	0.000618	CcSEcCtD
Ceftriaxone—Rash—Goserelin—prostate cancer	0.000149	0.000617	CcSEcCtD
Ceftriaxone—Dermatitis—Goserelin—prostate cancer	0.000149	0.000616	CcSEcCtD
Ceftriaxone—Vomiting—Conjugated Estrogens—prostate cancer	0.000149	0.000616	CcSEcCtD
Ceftriaxone—Urticaria—Estradiol—prostate cancer	0.000148	0.000616	CcSEcCtD
Ceftriaxone—Abdominal pain—Estradiol—prostate cancer	0.000148	0.000613	CcSEcCtD
Ceftriaxone—Body temperature increased—Estradiol—prostate cancer	0.000148	0.000613	CcSEcCtD
Ceftriaxone—Headache—Goserelin—prostate cancer	0.000148	0.000613	CcSEcCtD
Ceftriaxone—Rash—Conjugated Estrogens—prostate cancer	0.000147	0.000611	CcSEcCtD
Ceftriaxone—Chills—Capecitabine—prostate cancer	0.000147	0.000611	CcSEcCtD
Ceftriaxone—Dermatitis—Conjugated Estrogens—prostate cancer	0.000147	0.000611	CcSEcCtD
Ceftriaxone—Haemoglobin—Prednisone—prostate cancer	0.000147	0.00061	CcSEcCtD
Ceftriaxone—Headache—Conjugated Estrogens—prostate cancer	0.000146	0.000607	CcSEcCtD
Ceftriaxone—Haemorrhage—Prednisone—prostate cancer	0.000146	0.000607	CcSEcCtD
Ceftriaxone—Anaphylactic shock—Etoposide—prostate cancer	0.000145	0.000601	CcSEcCtD
Ceftriaxone—Dysgeusia—Docetaxel—prostate cancer	0.000144	0.0006	CcSEcCtD
Ceftriaxone—Infection—Etoposide—prostate cancer	0.000144	0.000597	CcSEcCtD
Ceftriaxone—Ataxia—Doxorubicin—prostate cancer	0.000144	0.000597	CcSEcCtD
Ceftriaxone—Feeling abnormal—Mitoxantrone—prostate cancer	0.000144	0.000596	CcSEcCtD
Ceftriaxone—Blood creatinine increased—Doxorubicin—prostate cancer	0.000143	0.000594	CcSEcCtD
Ceftriaxone—Gastrointestinal pain—Mitoxantrone—prostate cancer	0.000142	0.000591	CcSEcCtD
Ceftriaxone—Thrombocytopenia—Etoposide—prostate cancer	0.000142	0.000589	CcSEcCtD
Ceftriaxone—Eosinophilia—Epirubicin—prostate cancer	0.000141	0.000587	CcSEcCtD
Ceftriaxone—Flatulence—Capecitabine—prostate cancer	0.000141	0.000584	CcSEcCtD
Ceftriaxone—Nausea—Goserelin—prostate cancer	0.00014	0.000581	CcSEcCtD
Ceftriaxone—Hyperhidrosis—Etoposide—prostate cancer	0.00014	0.000581	CcSEcCtD
Ceftriaxone—Pancreatitis—Epirubicin—prostate cancer	0.00014	0.000581	CcSEcCtD
Ceftriaxone—Dysgeusia—Capecitabine—prostate cancer	0.00014	0.000581	CcSEcCtD
Ceftriaxone—Abdominal pain upper—Doxorubicin—prostate cancer	0.00014	0.00058	CcSEcCtD
Ceftriaxone—Nausea—Conjugated Estrogens—prostate cancer	0.000139	0.000576	CcSEcCtD
Ceftriaxone—Urticaria—Mitoxantrone—prostate cancer	0.000138	0.000574	CcSEcCtD
Ceftriaxone—Hypersensitivity—Estradiol—prostate cancer	0.000138	0.000572	CcSEcCtD
Ceftriaxone—Abdominal pain—Mitoxantrone—prostate cancer	0.000138	0.000571	CcSEcCtD
Ceftriaxone—Body temperature increased—Mitoxantrone—prostate cancer	0.000138	0.000571	CcSEcCtD
Ceftriaxone—Toxic epidermal necrolysis—Doxorubicin—prostate cancer	0.000138	0.000571	CcSEcCtD
Ceftriaxone—Aspartate aminotransferase increased—Doxorubicin—prostate cancer	0.000138	0.000571	CcSEcCtD
Ceftriaxone—Anaemia—Docetaxel—prostate cancer	0.000136	0.000566	CcSEcCtD
Ceftriaxone—Flushing—Prednisone—prostate cancer	0.000136	0.000563	CcSEcCtD
Ceftriaxone—Neutropenia—Epirubicin—prostate cancer	0.000134	0.000554	CcSEcCtD
Ceftriaxone—Ill-defined disorder—Capecitabine—prostate cancer	0.000133	0.00055	CcSEcCtD
Ceftriaxone—Pruritus—Estradiol—prostate cancer	0.000132	0.000549	CcSEcCtD
Ceftriaxone—Leukopenia—Docetaxel—prostate cancer	0.000132	0.000548	CcSEcCtD
Ceftriaxone—Anaemia—Capecitabine—prostate cancer	0.000132	0.000548	CcSEcCtD
Ceftriaxone—Eosinophilia—Doxorubicin—prostate cancer	0.000131	0.000543	CcSEcCtD
Ceftriaxone—Palpitations—Docetaxel—prostate cancer	0.00013	0.000541	CcSEcCtD
Ceftriaxone—Paraesthesia—Etoposide—prostate cancer	0.00013	0.00054	CcSEcCtD
Ceftriaxone—Pancreatitis—Doxorubicin—prostate cancer	0.00013	0.000538	CcSEcCtD
Ceftriaxone—Malaise—Capecitabine—prostate cancer	0.000129	0.000535	CcSEcCtD
Ceftriaxone—Hypersensitivity—Mitoxantrone—prostate cancer	0.000128	0.000533	CcSEcCtD
Ceftriaxone—Diarrhoea—Estradiol—prostate cancer	0.000128	0.000531	CcSEcCtD
Ceftriaxone—Leukopenia—Capecitabine—prostate cancer	0.000128	0.000531	CcSEcCtD
Ceftriaxone—Convulsion—Docetaxel—prostate cancer	0.000128	0.00053	CcSEcCtD
Ceftriaxone—Stevens-Johnson syndrome—Epirubicin—prostate cancer	0.000126	0.000524	CcSEcCtD
Ceftriaxone—Palpitations—Capecitabine—prostate cancer	0.000126	0.000524	CcSEcCtD
Ceftriaxone—Renal failure—Epirubicin—prostate cancer	0.000125	0.000519	CcSEcCtD
Ceftriaxone—Jaundice—Epirubicin—prostate cancer	0.000124	0.000515	CcSEcCtD
Ceftriaxone—Stomatitis—Epirubicin—prostate cancer	0.000124	0.000515	CcSEcCtD
Ceftriaxone—Pain—Etoposide—prostate cancer	0.000124	0.000514	CcSEcCtD
Ceftriaxone—Dizziness—Estradiol—prostate cancer	0.000124	0.000513	CcSEcCtD
Ceftriaxone—Neutropenia—Doxorubicin—prostate cancer	0.000124	0.000513	CcSEcCtD
Ceftriaxone—Haematuria—Epirubicin—prostate cancer	0.000121	0.000504	CcSEcCtD
Ceftriaxone—Oedema—Docetaxel—prostate cancer	0.00012	0.0005	CcSEcCtD
Ceftriaxone—Anaphylactic shock—Docetaxel—prostate cancer	0.00012	0.0005	CcSEcCtD
Ceftriaxone—Discomfort—Capecitabine—prostate cancer	0.00012	0.000499	CcSEcCtD
Ceftriaxone—Epistaxis—Epirubicin—prostate cancer	0.00012	0.000498	CcSEcCtD
Ceftriaxone—Infection—Docetaxel—prostate cancer	0.00012	0.000496	CcSEcCtD
Ceftriaxone—Feeling abnormal—Etoposide—prostate cancer	0.000119	0.000495	CcSEcCtD
Ceftriaxone—Diarrhoea—Mitoxantrone—prostate cancer	0.000119	0.000495	CcSEcCtD
Ceftriaxone—Vomiting—Estradiol—prostate cancer	0.000119	0.000493	CcSEcCtD
Ceftriaxone—Agranulocytosis—Epirubicin—prostate cancer	0.000119	0.000493	CcSEcCtD
Ceftriaxone—Gastrointestinal pain—Etoposide—prostate cancer	0.000118	0.000492	CcSEcCtD
Ceftriaxone—Ill-defined disorder—Prednisone—prostate cancer	0.000118	0.00049	CcSEcCtD
Ceftriaxone—Thrombocytopenia—Docetaxel—prostate cancer	0.000118	0.000489	CcSEcCtD
Ceftriaxone—Rash—Estradiol—prostate cancer	0.000118	0.000489	CcSEcCtD
Ceftriaxone—Dermatitis—Estradiol—prostate cancer	0.000118	0.000489	CcSEcCtD
Ceftriaxone—Anaemia—Prednisone—prostate cancer	0.000118	0.000488	CcSEcCtD
Ceftriaxone—Headache—Estradiol—prostate cancer	0.000117	0.000486	CcSEcCtD
Ceftriaxone—Agitation—Prednisone—prostate cancer	0.000117	0.000485	CcSEcCtD
Ceftriaxone—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	0.000117	0.000485	CcSEcCtD
Ceftriaxone—Oedema—Capecitabine—prostate cancer	0.000117	0.000484	CcSEcCtD
Ceftriaxone—Renal failure—Doxorubicin—prostate cancer	0.000116	0.000481	CcSEcCtD
Ceftriaxone—Infection—Capecitabine—prostate cancer	0.000116	0.000481	CcSEcCtD
Ceftriaxone—Urticaria—Etoposide—prostate cancer	0.000115	0.000478	CcSEcCtD
Ceftriaxone—Haemoglobin—Epirubicin—prostate cancer	0.000115	0.000477	CcSEcCtD
Ceftriaxone—Stomatitis—Doxorubicin—prostate cancer	0.000115	0.000477	CcSEcCtD
Ceftriaxone—Jaundice—Doxorubicin—prostate cancer	0.000115	0.000477	CcSEcCtD
Ceftriaxone—Malaise—Prednisone—prostate cancer	0.000115	0.000476	CcSEcCtD
Ceftriaxone—Abdominal pain—Etoposide—prostate cancer	0.000115	0.000475	CcSEcCtD
Ceftriaxone—Body temperature increased—Etoposide—prostate cancer	0.000115	0.000475	CcSEcCtD
Ceftriaxone—Haemorrhage—Epirubicin—prostate cancer	0.000114	0.000474	CcSEcCtD
Ceftriaxone—Thrombocytopenia—Capecitabine—prostate cancer	0.000114	0.000474	CcSEcCtD
Ceftriaxone—Hyperhidrosis—Capecitabine—prostate cancer	0.000113	0.000468	CcSEcCtD
Ceftriaxone—Haematuria—Doxorubicin—prostate cancer	0.000112	0.000466	CcSEcCtD
Ceftriaxone—Epistaxis—Doxorubicin—prostate cancer	0.000111	0.000461	CcSEcCtD
Ceftriaxone—Nausea—Estradiol—prostate cancer	0.000111	0.000461	CcSEcCtD
Ceftriaxone—Vomiting—Mitoxantrone—prostate cancer	0.000111	0.00046	CcSEcCtD
Ceftriaxone—Convulsion—Prednisone—prostate cancer	0.00011	0.000458	CcSEcCtD
Ceftriaxone—Agranulocytosis—Doxorubicin—prostate cancer	0.00011	0.000456	CcSEcCtD
Ceftriaxone—Rash—Mitoxantrone—prostate cancer	0.00011	0.000456	CcSEcCtD
Ceftriaxone—Dermatitis—Mitoxantrone—prostate cancer	0.00011	0.000455	CcSEcCtD
Ceftriaxone—Headache—Mitoxantrone—prostate cancer	0.000109	0.000453	CcSEcCtD
Ceftriaxone—Paraesthesia—Docetaxel—prostate cancer	0.000108	0.000449	CcSEcCtD
Ceftriaxone—Erythema multiforme—Epirubicin—prostate cancer	0.000108	0.000449	CcSEcCtD
Ceftriaxone—Discomfort—Prednisone—prostate cancer	0.000107	0.000444	CcSEcCtD
Ceftriaxone—Hypersensitivity—Etoposide—prostate cancer	0.000107	0.000443	CcSEcCtD
Ceftriaxone—Haemoglobin—Doxorubicin—prostate cancer	0.000106	0.000441	CcSEcCtD
Ceftriaxone—Flushing—Epirubicin—prostate cancer	0.000106	0.00044	CcSEcCtD
Ceftriaxone—Dyspepsia—Docetaxel—prostate cancer	0.000106	0.00044	CcSEcCtD
Ceftriaxone—Haemorrhage—Doxorubicin—prostate cancer	0.000106	0.000439	CcSEcCtD
Ceftriaxone—Paraesthesia—Capecitabine—prostate cancer	0.000105	0.000434	CcSEcCtD
Ceftriaxone—Oedema—Prednisone—prostate cancer	0.000104	0.000431	CcSEcCtD
Ceftriaxone—Anaphylactic shock—Prednisone—prostate cancer	0.000104	0.000431	CcSEcCtD
Ceftriaxone—Nausea—Mitoxantrone—prostate cancer	0.000103	0.000429	CcSEcCtD
Ceftriaxone—Infection—Prednisone—prostate cancer	0.000103	0.000428	CcSEcCtD
Ceftriaxone—Pain—Docetaxel—prostate cancer	0.000103	0.000427	CcSEcCtD
Ceftriaxone—Dyspepsia—Capecitabine—prostate cancer	0.000103	0.000426	CcSEcCtD
Ceftriaxone—Chills—Epirubicin—prostate cancer	0.000103	0.000426	CcSEcCtD
Ceftriaxone—Pruritus—Etoposide—prostate cancer	0.000102	0.000425	CcSEcCtD
Ceftriaxone—Hyperhidrosis—Prednisone—prostate cancer	0.0001	0.000417	CcSEcCtD
Ceftriaxone—Erythema multiforme—Doxorubicin—prostate cancer	0.0001	0.000415	CcSEcCtD
Ceftriaxone—Pain—Capecitabine—prostate cancer	9.97e-05	0.000414	CcSEcCtD
Ceftriaxone—Feeling abnormal—Docetaxel—prostate cancer	9.92e-05	0.000412	CcSEcCtD
Ceftriaxone—Diarrhoea—Etoposide—prostate cancer	9.91e-05	0.000411	CcSEcCtD
Ceftriaxone—Gastrointestinal pain—Docetaxel—prostate cancer	9.85e-05	0.000409	CcSEcCtD
Ceftriaxone—Flushing—Doxorubicin—prostate cancer	9.82e-05	0.000407	CcSEcCtD
Ceftriaxone—Flatulence—Epirubicin—prostate cancer	9.81e-05	0.000407	CcSEcCtD
Ceftriaxone—Dysgeusia—Epirubicin—prostate cancer	9.74e-05	0.000404	CcSEcCtD
Ceftriaxone—Feeling abnormal—Capecitabine—prostate cancer	9.61e-05	0.000399	CcSEcCtD
Ceftriaxone—Dizziness—Etoposide—prostate cancer	9.58e-05	0.000398	CcSEcCtD
Ceftriaxone—Gastrointestinal pain—Capecitabine—prostate cancer	9.53e-05	0.000396	CcSEcCtD
Ceftriaxone—Abdominal pain—Docetaxel—prostate cancer	9.52e-05	0.000395	CcSEcCtD
Ceftriaxone—Body temperature increased—Docetaxel—prostate cancer	9.52e-05	0.000395	CcSEcCtD
Ceftriaxone—Chills—Doxorubicin—prostate cancer	9.49e-05	0.000394	CcSEcCtD
Ceftriaxone—Paraesthesia—Prednisone—prostate cancer	9.32e-05	0.000387	CcSEcCtD
Ceftriaxone—Urticaria—Capecitabine—prostate cancer	9.26e-05	0.000384	CcSEcCtD
Ceftriaxone—Ill-defined disorder—Epirubicin—prostate cancer	9.23e-05	0.000383	CcSEcCtD
Ceftriaxone—Body temperature increased—Capecitabine—prostate cancer	9.22e-05	0.000382	CcSEcCtD
Ceftriaxone—Abdominal pain—Capecitabine—prostate cancer	9.22e-05	0.000382	CcSEcCtD
Ceftriaxone—Vomiting—Etoposide—prostate cancer	9.21e-05	0.000382	CcSEcCtD
Ceftriaxone—Anaemia—Epirubicin—prostate cancer	9.2e-05	0.000382	CcSEcCtD
Ceftriaxone—Agitation—Epirubicin—prostate cancer	9.14e-05	0.00038	CcSEcCtD
Ceftriaxone—Dyspepsia—Prednisone—prostate cancer	9.14e-05	0.000379	CcSEcCtD
Ceftriaxone—Rash—Etoposide—prostate cancer	9.13e-05	0.000379	CcSEcCtD
Ceftriaxone—Dermatitis—Etoposide—prostate cancer	9.13e-05	0.000379	CcSEcCtD
Ceftriaxone—Headache—Etoposide—prostate cancer	9.08e-05	0.000377	CcSEcCtD
Ceftriaxone—Flatulence—Doxorubicin—prostate cancer	9.07e-05	0.000377	CcSEcCtD
Ceftriaxone—Dysgeusia—Doxorubicin—prostate cancer	9.02e-05	0.000374	CcSEcCtD
Ceftriaxone—Malaise—Epirubicin—prostate cancer	8.97e-05	0.000372	CcSEcCtD
Ceftriaxone—Leukopenia—Epirubicin—prostate cancer	8.91e-05	0.00037	CcSEcCtD
Ceftriaxone—Hypersensitivity—Docetaxel—prostate cancer	8.87e-05	0.000368	CcSEcCtD
Ceftriaxone—Palpitations—Epirubicin—prostate cancer	8.79e-05	0.000365	CcSEcCtD
Ceftriaxone—Convulsion—Epirubicin—prostate cancer	8.62e-05	0.000358	CcSEcCtD
Ceftriaxone—Nausea—Etoposide—prostate cancer	8.61e-05	0.000357	CcSEcCtD
Ceftriaxone—Hypersensitivity—Capecitabine—prostate cancer	8.59e-05	0.000356	CcSEcCtD
Ceftriaxone—Feeling abnormal—Prednisone—prostate cancer	8.56e-05	0.000355	CcSEcCtD
Ceftriaxone—Ill-defined disorder—Doxorubicin—prostate cancer	8.54e-05	0.000355	CcSEcCtD
Ceftriaxone—Pruritus—Docetaxel—prostate cancer	8.52e-05	0.000354	CcSEcCtD
Ceftriaxone—Anaemia—Doxorubicin—prostate cancer	8.51e-05	0.000353	CcSEcCtD
Ceftriaxone—Gastrointestinal pain—Prednisone—prostate cancer	8.49e-05	0.000352	CcSEcCtD
Ceftriaxone—Agitation—Doxorubicin—prostate cancer	8.46e-05	0.000351	CcSEcCtD
Ceftriaxone—Discomfort—Epirubicin—prostate cancer	8.37e-05	0.000347	CcSEcCtD
Ceftriaxone—Malaise—Doxorubicin—prostate cancer	8.3e-05	0.000345	CcSEcCtD
Ceftriaxone—Urticaria—Prednisone—prostate cancer	8.25e-05	0.000342	CcSEcCtD
Ceftriaxone—Pruritus—Capecitabine—prostate cancer	8.25e-05	0.000342	CcSEcCtD
Ceftriaxone—Leukopenia—Doxorubicin—prostate cancer	8.24e-05	0.000342	CcSEcCtD
Ceftriaxone—Diarrhoea—Docetaxel—prostate cancer	8.24e-05	0.000342	CcSEcCtD
Ceftriaxone—Body temperature increased—Prednisone—prostate cancer	8.21e-05	0.000341	CcSEcCtD
Ceftriaxone—Abdominal pain—Prednisone—prostate cancer	8.21e-05	0.000341	CcSEcCtD
Ceftriaxone—Palpitations—Doxorubicin—prostate cancer	8.14e-05	0.000338	CcSEcCtD
Ceftriaxone—Oedema—Epirubicin—prostate cancer	8.12e-05	0.000337	CcSEcCtD
Ceftriaxone—Anaphylactic shock—Epirubicin—prostate cancer	8.12e-05	0.000337	CcSEcCtD
Ceftriaxone—Infection—Epirubicin—prostate cancer	8.07e-05	0.000335	CcSEcCtD
Ceftriaxone—Convulsion—Doxorubicin—prostate cancer	7.98e-05	0.000331	CcSEcCtD
Ceftriaxone—Diarrhoea—Capecitabine—prostate cancer	7.98e-05	0.000331	CcSEcCtD
Ceftriaxone—Dizziness—Docetaxel—prostate cancer	7.96e-05	0.00033	CcSEcCtD
Ceftriaxone—Thrombocytopenia—Epirubicin—prostate cancer	7.95e-05	0.00033	CcSEcCtD
Ceftriaxone—Hyperhidrosis—Epirubicin—prostate cancer	7.85e-05	0.000326	CcSEcCtD
Ceftriaxone—Discomfort—Doxorubicin—prostate cancer	7.74e-05	0.000321	CcSEcCtD
Ceftriaxone—Dizziness—Capecitabine—prostate cancer	7.71e-05	0.00032	CcSEcCtD
Ceftriaxone—Vomiting—Docetaxel—prostate cancer	7.66e-05	0.000318	CcSEcCtD
Ceftriaxone—Hypersensitivity—Prednisone—prostate cancer	7.65e-05	0.000318	CcSEcCtD
Ceftriaxone—Rash—Docetaxel—prostate cancer	7.59e-05	0.000315	CcSEcCtD
Ceftriaxone—Dermatitis—Docetaxel—prostate cancer	7.58e-05	0.000315	CcSEcCtD
Ceftriaxone—Headache—Docetaxel—prostate cancer	7.54e-05	0.000313	CcSEcCtD
Ceftriaxone—Oedema—Doxorubicin—prostate cancer	7.51e-05	0.000312	CcSEcCtD
Ceftriaxone—Anaphylactic shock—Doxorubicin—prostate cancer	7.51e-05	0.000312	CcSEcCtD
Ceftriaxone—Infection—Doxorubicin—prostate cancer	7.47e-05	0.00031	CcSEcCtD
Ceftriaxone—Vomiting—Capecitabine—prostate cancer	7.41e-05	0.000308	CcSEcCtD
Ceftriaxone—Thrombocytopenia—Doxorubicin—prostate cancer	7.36e-05	0.000305	CcSEcCtD
Ceftriaxone—Rash—Capecitabine—prostate cancer	7.35e-05	0.000305	CcSEcCtD
Ceftriaxone—Pruritus—Prednisone—prostate cancer	7.35e-05	0.000305	CcSEcCtD
Ceftriaxone—Dermatitis—Capecitabine—prostate cancer	7.34e-05	0.000305	CcSEcCtD
Ceftriaxone—Headache—Capecitabine—prostate cancer	7.3e-05	0.000303	CcSEcCtD
Ceftriaxone—Paraesthesia—Epirubicin—prostate cancer	7.29e-05	0.000303	CcSEcCtD
Ceftriaxone—Hyperhidrosis—Doxorubicin—prostate cancer	7.26e-05	0.000301	CcSEcCtD
Ceftriaxone—Nausea—Docetaxel—prostate cancer	7.15e-05	0.000297	CcSEcCtD
Ceftriaxone—Dyspepsia—Epirubicin—prostate cancer	7.15e-05	0.000297	CcSEcCtD
Ceftriaxone—Diarrhoea—Prednisone—prostate cancer	7.1e-05	0.000295	CcSEcCtD
Ceftriaxone—Pain—Epirubicin—prostate cancer	6.94e-05	0.000288	CcSEcCtD
Ceftriaxone—Nausea—Capecitabine—prostate cancer	6.92e-05	0.000287	CcSEcCtD
Ceftriaxone—Dizziness—Prednisone—prostate cancer	6.87e-05	0.000285	CcSEcCtD
Ceftriaxone—Paraesthesia—Doxorubicin—prostate cancer	6.75e-05	0.00028	CcSEcCtD
Ceftriaxone—Feeling abnormal—Epirubicin—prostate cancer	6.69e-05	0.000278	CcSEcCtD
Ceftriaxone—Gastrointestinal pain—Epirubicin—prostate cancer	6.64e-05	0.000276	CcSEcCtD
Ceftriaxone—Dyspepsia—Doxorubicin—prostate cancer	6.61e-05	0.000275	CcSEcCtD
Ceftriaxone—Vomiting—Prednisone—prostate cancer	6.6e-05	0.000274	CcSEcCtD
Ceftriaxone—Rash—Prednisone—prostate cancer	6.55e-05	0.000272	CcSEcCtD
Ceftriaxone—Dermatitis—Prednisone—prostate cancer	6.54e-05	0.000271	CcSEcCtD
Ceftriaxone—Headache—Prednisone—prostate cancer	6.5e-05	0.00027	CcSEcCtD
Ceftriaxone—Urticaria—Epirubicin—prostate cancer	6.45e-05	0.000268	CcSEcCtD
Ceftriaxone—Pain—Doxorubicin—prostate cancer	6.43e-05	0.000267	CcSEcCtD
Ceftriaxone—Body temperature increased—Epirubicin—prostate cancer	6.42e-05	0.000266	CcSEcCtD
Ceftriaxone—Abdominal pain—Epirubicin—prostate cancer	6.42e-05	0.000266	CcSEcCtD
Ceftriaxone—Feeling abnormal—Doxorubicin—prostate cancer	6.19e-05	0.000257	CcSEcCtD
Ceftriaxone—Nausea—Prednisone—prostate cancer	6.17e-05	0.000256	CcSEcCtD
Ceftriaxone—Gastrointestinal pain—Doxorubicin—prostate cancer	6.14e-05	0.000255	CcSEcCtD
Ceftriaxone—Hypersensitivity—Epirubicin—prostate cancer	5.98e-05	0.000248	CcSEcCtD
Ceftriaxone—Urticaria—Doxorubicin—prostate cancer	5.97e-05	0.000248	CcSEcCtD
Ceftriaxone—Abdominal pain—Doxorubicin—prostate cancer	5.94e-05	0.000247	CcSEcCtD
Ceftriaxone—Body temperature increased—Doxorubicin—prostate cancer	5.94e-05	0.000247	CcSEcCtD
Ceftriaxone—Pruritus—Epirubicin—prostate cancer	5.75e-05	0.000238	CcSEcCtD
Ceftriaxone—Diarrhoea—Epirubicin—prostate cancer	5.56e-05	0.000231	CcSEcCtD
Ceftriaxone—Hypersensitivity—Doxorubicin—prostate cancer	5.54e-05	0.00023	CcSEcCtD
Ceftriaxone—Dizziness—Epirubicin—prostate cancer	5.37e-05	0.000223	CcSEcCtD
Ceftriaxone—Pruritus—Doxorubicin—prostate cancer	5.32e-05	0.000221	CcSEcCtD
Ceftriaxone—Vomiting—Epirubicin—prostate cancer	5.16e-05	0.000214	CcSEcCtD
Ceftriaxone—Diarrhoea—Doxorubicin—prostate cancer	5.14e-05	0.000213	CcSEcCtD
Ceftriaxone—Rash—Epirubicin—prostate cancer	5.12e-05	0.000213	CcSEcCtD
Ceftriaxone—Dermatitis—Epirubicin—prostate cancer	5.12e-05	0.000212	CcSEcCtD
Ceftriaxone—Headache—Epirubicin—prostate cancer	5.09e-05	0.000211	CcSEcCtD
Ceftriaxone—Dizziness—Doxorubicin—prostate cancer	4.97e-05	0.000206	CcSEcCtD
Ceftriaxone—Nausea—Epirubicin—prostate cancer	4.82e-05	0.0002	CcSEcCtD
Ceftriaxone—Vomiting—Doxorubicin—prostate cancer	4.78e-05	0.000198	CcSEcCtD
Ceftriaxone—Rash—Doxorubicin—prostate cancer	4.74e-05	0.000197	CcSEcCtD
Ceftriaxone—Dermatitis—Doxorubicin—prostate cancer	4.73e-05	0.000196	CcSEcCtD
Ceftriaxone—Headache—Doxorubicin—prostate cancer	4.71e-05	0.000195	CcSEcCtD
Ceftriaxone—SLC15A1—Transmembrane transport of small molecules—RXRA—prostate cancer	4.48e-05	0.000447	CbGpPWpGaD
Ceftriaxone—Nausea—Doxorubicin—prostate cancer	4.46e-05	0.000185	CcSEcCtD
Ceftriaxone—SLC22A6—Transmembrane transport of small molecules—PRKACB—prostate cancer	4.4e-05	0.000439	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—TYMS—prostate cancer	4.38e-05	0.000437	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—CYP7B1—prostate cancer	4.38e-05	0.000437	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—GSTM1—prostate cancer	4.33e-05	0.000432	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—HSD17B3—prostate cancer	4.28e-05	0.000427	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—ACSL4—prostate cancer	4.28e-05	0.000427	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—SLC26A4—prostate cancer	4.26e-05	0.000426	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—SLC12A2—prostate cancer	4.26e-05	0.000426	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—LPL—prostate cancer	4.25e-05	0.000424	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—ITGA6—prostate cancer	4.19e-05	0.000418	CbGpPWpGaD
Ceftriaxone—SLC22A8—Transmembrane transport of small molecules—NCOA1—prostate cancer	4.19e-05	0.000418	CbGpPWpGaD
Ceftriaxone—SLC22A6—Transmembrane transport of small molecules—NCOA2—prostate cancer	4.15e-05	0.000414	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—PRKCQ—prostate cancer	4.11e-05	0.00041	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—CYP1A1—prostate cancer	4.1e-05	0.000409	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—ERCC2—prostate cancer	4.07e-05	0.000406	CbGpPWpGaD
Ceftriaxone—ALB—SLC-mediated transmembrane transport—SLC5A5—prostate cancer	4.05e-05	0.000404	CbGpPWpGaD
Ceftriaxone—ALB—Selenium Micronutrient Network—PTGS2—prostate cancer	4.02e-05	0.000401	CbGpPWpGaD
Ceftriaxone—SLC22A11—Transmembrane transport of small molecules—PPARA—prostate cancer	3.99e-05	0.000398	CbGpPWpGaD
Ceftriaxone—SLC22A8—Transmembrane transport of small molecules—RXRA—prostate cancer	3.98e-05	0.000398	CbGpPWpGaD
Ceftriaxone—SLC22A6—Transmembrane transport of small molecules—SLC5A5—prostate cancer	3.96e-05	0.000395	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—CD9—prostate cancer	3.94e-05	0.000393	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—HAO1—prostate cancer	3.9e-05	0.000389	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—MTHFR—prostate cancer	3.82e-05	0.000382	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—VAV3—prostate cancer	3.77e-05	0.000376	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—PPARA—prostate cancer	3.75e-05	0.000375	CbGpPWpGaD
Ceftriaxone—SLC15A2—Transmembrane transport of small molecules—PPARA—prostate cancer	3.69e-05	0.000368	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—ITPR1—prostate cancer	3.65e-05	0.000365	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—HSD3B1—prostate cancer	3.64e-05	0.000363	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—CLU—prostate cancer	3.56e-05	0.000355	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—CAV1—prostate cancer	3.53e-05	0.000352	CbGpPWpGaD
Ceftriaxone—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—prostate cancer	3.52e-05	0.000351	CbGpPWpGaD
Ceftriaxone—SLC22A6—Transmembrane transport of small molecules—NCOA1—prostate cancer	3.5e-05	0.000349	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—TBXAS1—prostate cancer	3.49e-05	0.000348	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—SLC22A3—prostate cancer	3.46e-05	0.000345	CbGpPWpGaD
Ceftriaxone—SLC15A1—Transmembrane transport of small molecules—PPARA—prostate cancer	3.42e-05	0.000341	CbGpPWpGaD
Ceftriaxone—ALB—Platelet degranulation—VEGFA—prostate cancer	3.42e-05	0.000341	CbGpPWpGaD
Ceftriaxone—ALB—Vitamin B12 Metabolism—IL6—prostate cancer	3.39e-05	0.000338	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—ABCG5—prostate cancer	3.36e-05	0.000335	CbGpPWpGaD
Ceftriaxone—SLC22A6—Transmembrane transport of small molecules—RXRA—prostate cancer	3.32e-05	0.000332	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—GRB7—prostate cancer	3.26e-05	0.000325	CbGpPWpGaD
Ceftriaxone—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—prostate cancer	3.25e-05	0.000325	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—HSD3B2—prostate cancer	3.24e-05	0.000324	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—ITGB3—prostate cancer	3.23e-05	0.000323	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—PIK3CG—prostate cancer	3.21e-05	0.000321	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—ABCG5—prostate cancer	3.19e-05	0.000319	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—CSAD—prostate cancer	3.18e-05	0.000317	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—CBR1—prostate cancer	3.18e-05	0.000317	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—TST—prostate cancer	3.18e-05	0.000317	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—ADI1—prostate cancer	3.18e-05	0.000317	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—PSAT1—prostate cancer	3.18e-05	0.000317	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—GRHL1—prostate cancer	3.18e-05	0.000317	CbGpPWpGaD
Ceftriaxone—SLC22A11—Transmembrane transport of small molecules—CREBBP—prostate cancer	3.17e-05	0.000316	CbGpPWpGaD
Ceftriaxone—ALB—Platelet degranulation—TGFB1—prostate cancer	3.14e-05	0.000313	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—LRP2—prostate cancer	3.11e-05	0.00031	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—GNG5—prostate cancer	3.1e-05	0.000309	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—P4HB—prostate cancer	3.05e-05	0.000304	CbGpPWpGaD
Ceftriaxone—SLC22A8—Transmembrane transport of small molecules—PPARA—prostate cancer	3.04e-05	0.000304	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—INS—prostate cancer	3.04e-05	0.000304	CbGpPWpGaD
Ceftriaxone—ALB—Folate Metabolism—TP53—prostate cancer	3.01e-05	0.0003	CbGpPWpGaD
Ceftriaxone—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—prostate cancer	2.99e-05	0.000298	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—CREBBP—prostate cancer	2.98e-05	0.000297	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—UGT2B15—prostate cancer	2.96e-05	0.000295	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—GRHPR—prostate cancer	2.96e-05	0.000295	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—UGT2B17—prostate cancer	2.96e-05	0.000295	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—CKMT2—prostate cancer	2.96e-05	0.000295	CbGpPWpGaD
Ceftriaxone—SLC15A2—Transmembrane transport of small molecules—CREBBP—prostate cancer	2.93e-05	0.000292	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—SULT2A1—prostate cancer	2.89e-05	0.000288	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—MED12—prostate cancer	2.84e-05	0.000284	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—PIK3CD—prostate cancer	2.83e-05	0.000282	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—SLC22A1—prostate cancer	2.82e-05	0.000281	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—MBTPS1—prostate cancer	2.78e-05	0.000277	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—PGAM2—prostate cancer	2.78e-05	0.000277	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—SULT2B1—prostate cancer	2.78e-05	0.000277	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—RFK—prostate cancer	2.78e-05	0.000277	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—GSTM3—prostate cancer	2.78e-05	0.000277	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—NAGLU—prostate cancer	2.78e-05	0.000277	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—AOX1—prostate cancer	2.78e-05	0.000277	CbGpPWpGaD
Ceftriaxone—ALB—Folate Metabolism—IL6—prostate cancer	2.76e-05	0.000275	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—NCOA3—prostate cancer	2.72e-05	0.000271	CbGpPWpGaD
Ceftriaxone—SLC15A1—Transmembrane transport of small molecules—CREBBP—prostate cancer	2.72e-05	0.000271	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—GNG5—prostate cancer	2.68e-05	0.000268	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—NOS3—prostate cancer	2.67e-05	0.000266	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—PRKACB—prostate cancer	2.64e-05	0.000264	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—CYP3A43—prostate cancer	2.64e-05	0.000263	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—AMACR—prostate cancer	2.64e-05	0.000263	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—NAT1—prostate cancer	2.64e-05	0.000263	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—DEGS1—prostate cancer	2.64e-05	0.000263	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—SRD5A2—prostate cancer	2.64e-05	0.000263	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—HPGDS—prostate cancer	2.59e-05	0.000259	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—CYP2C19—prostate cancer	2.58e-05	0.000257	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—THBS1—prostate cancer	2.57e-05	0.000257	CbGpPWpGaD
Ceftriaxone—SLC22A6—Transmembrane transport of small molecules—PPARA—prostate cancer	2.54e-05	0.000253	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—PIK3CG—prostate cancer	2.53e-05	0.000253	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—HSD17B1—prostate cancer	2.51e-05	0.000251	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—ACHE—prostate cancer	2.51e-05	0.000251	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—EGF—prostate cancer	2.5e-05	0.00025	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—PRKCZ—prostate cancer	2.49e-05	0.000249	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—PIK3CB—prostate cancer	2.46e-05	0.000246	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—PTGS2—prostate cancer	2.44e-05	0.000244	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—AKR1C3—prostate cancer	2.42e-05	0.000241	CbGpPWpGaD
Ceftriaxone—SLC22A8—Transmembrane transport of small molecules—CREBBP—prostate cancer	2.42e-05	0.000241	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—PRKACB—prostate cancer	2.4e-05	0.00024	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—CYP17A1—prostate cancer	2.38e-05	0.000237	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—IGF1—prostate cancer	2.32e-05	0.000232	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—PRKACB—prostate cancer	2.29e-05	0.000228	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—NCOA2—prostate cancer	2.27e-05	0.000226	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—HPGD—prostate cancer	2.24e-05	0.000224	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—B4GALT4—prostate cancer	2.24e-05	0.000224	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—PIK3CD—prostate cancer	2.23e-05	0.000222	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—SERPINE1—prostate cancer	2.2e-05	0.00022	CbGpPWpGaD
Ceftriaxone—ALB—Selenium Micronutrient Network—IL6—prostate cancer	2.19e-05	0.000218	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—NCOA2—prostate cancer	2.16e-05	0.000215	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—PTEN—prostate cancer	2.13e-05	0.000212	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—PRKCQ—prostate cancer	2.12e-05	0.000211	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—TNFRSF21—prostate cancer	2.11e-05	0.00021	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—PLAUR—prostate cancer	2.09e-05	0.000209	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—SLC5A5—prostate cancer	2.06e-05	0.000205	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—MTAP—prostate cancer	2.05e-05	0.000205	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—CYP7B1—prostate cancer	2.05e-05	0.000205	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—JAK2—prostate cancer	2.04e-05	0.000204	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—EP300—prostate cancer	2.03e-05	0.000203	CbGpPWpGaD
Ceftriaxone—SLC22A6—Transmembrane transport of small molecules—CREBBP—prostate cancer	2.02e-05	0.000201	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—CYP1B1—prostate cancer	2e-05	0.0002	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—SULT1E1—prostate cancer	2e-05	0.000199	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—SRD5A1—prostate cancer	2e-05	0.000199	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—VAV3—prostate cancer	1.94e-05	0.000194	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—PIK3CB—prostate cancer	1.94e-05	0.000194	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—GGT1—prostate cancer	1.94e-05	0.000194	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—NCOA1—prostate cancer	1.91e-05	0.000191	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—HSD17B3—prostate cancer	1.91e-05	0.00019	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—ACSL4—prostate cancer	1.91e-05	0.00019	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—ITPR1—prostate cancer	1.88e-05	0.000188	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—CYP19A1—prostate cancer	1.88e-05	0.000188	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—UMPS—prostate cancer	1.83e-05	0.000182	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—PHGDH—prostate cancer	1.83e-05	0.000182	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—ARG2—prostate cancer	1.83e-05	0.000182	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—RXRA—prostate cancer	1.82e-05	0.000181	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—NCOA1—prostate cancer	1.82e-05	0.000181	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—LDHB—prostate cancer	1.79e-05	0.000179	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—IL2—prostate cancer	1.78e-05	0.000178	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—CYP3A5—prostate cancer	1.76e-05	0.000175	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—RXRA—prostate cancer	1.73e-05	0.000172	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—UCP3—prostate cancer	1.7e-05	0.000169	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—TCN2—prostate cancer	1.7e-05	0.000169	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—PDHA1—prostate cancer	1.7e-05	0.000169	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—GSTA3—prostate cancer	1.7e-05	0.000169	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—ITGB3—prostate cancer	1.67e-05	0.000166	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—HSD3B1—prostate cancer	1.62e-05	0.000162	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—SLC22A3—prostate cancer	1.62e-05	0.000162	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—LPL—prostate cancer	1.57e-05	0.000157	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—SRC—prostate cancer	1.56e-05	0.000155	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—GSTA4—prostate cancer	1.55e-05	0.000155	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—TBXAS1—prostate cancer	1.55e-05	0.000155	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—CYP1A1—prostate cancer	1.52e-05	0.000151	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—VEGFA—prostate cancer	1.52e-05	0.000151	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—GSTA2—prostate cancer	1.51e-05	0.000151	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—PIK3CA—prostate cancer	1.5e-05	0.00015	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—ABCG5—prostate cancer	1.49e-05	0.000149	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—SULT1A1—prostate cancer	1.49e-05	0.000149	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—PLAU—prostate cancer	1.47e-05	0.000147	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—GSTA1—prostate cancer	1.46e-05	0.000146	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—HSD3B2—prostate cancer	1.44e-05	0.000144	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—NAT2—prostate cancer	1.44e-05	0.000144	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—GSTO1—prostate cancer	1.44e-05	0.000144	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—CAV1—prostate cancer	1.43e-05	0.000143	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—TGFB1—prostate cancer	1.39e-05	0.000139	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	1.39e-05	0.000139	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—PLCB2—prostate cancer	1.38e-05	0.000138	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—LRP2—prostate cancer	1.38e-05	0.000138	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—CYP2C18—prostate cancer	1.38e-05	0.000138	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—P4HB—prostate cancer	1.36e-05	0.000135	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—SLC22A1—prostate cancer	1.32e-05	0.000132	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—PPARA—prostate cancer	1.32e-05	0.000132	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—PIK3CG—prostate cancer	1.31e-05	0.00013	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	1.31e-05	0.00013	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—EGF—prostate cancer	1.29e-05	0.000129	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—SULT2A1—prostate cancer	1.29e-05	0.000128	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—MED12—prostate cancer	1.27e-05	0.000126	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—GNG5—prostate cancer	1.26e-05	0.000125	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—AKT1—prostate cancer	1.23e-05	0.000122	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—CREBBP—prostate cancer	1.21e-05	0.000121	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—NCOA3—prostate cancer	1.21e-05	0.000121	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—IGF1—prostate cancer	1.2e-05	0.000119	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	1.19e-05	0.000119	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—PIK3CA—prostate cancer	1.18e-05	0.000118	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—HPGDS—prostate cancer	1.15e-05	0.000115	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—PIK3CD—prostate cancer	1.15e-05	0.000115	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—CYP2C19—prostate cancer	1.15e-05	0.000114	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—SERPINE1—prostate cancer	1.14e-05	0.000113	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—ACHE—prostate cancer	1.12e-05	0.000112	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—GSTT1—prostate cancer	1.12e-05	0.000112	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—CYP2A6—prostate cancer	1.11e-05	0.00011	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	1.1e-05	0.00011	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—NOS3—prostate cancer	1.08e-05	0.000108	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—AKR1C3—prostate cancer	1.08e-05	0.000107	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—PRKACB—prostate cancer	1.07e-05	0.000107	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—CYP17A1—prostate cancer	1.06e-05	0.000106	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—JAK2—prostate cancer	1.05e-05	0.000105	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—CREBBP—prostate cancer	1.05e-05	0.000105	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	1.05e-05	0.000104	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—NCOA2—prostate cancer	1.01e-05	0.000101	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—PIK3CB—prostate cancer	1e-05	9.99e-05	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—AKT1—prostate cancer	9.67e-06	9.65e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—SLC5A5—prostate cancer	9.63e-06	9.61e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—CYP2E1—prostate cancer	9.41e-06	9.39e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—NQO1—prostate cancer	9.3e-06	9.29e-05	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—IL2—prostate cancer	9.19e-06	9.17e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—TH—prostate cancer	9.17e-06	9.15e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	9.11e-06	9.09e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—CYP3A4—prostate cancer	9.07e-06	9.06e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	9.03e-06	9.01e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—CYP1B1—prostate cancer	8.92e-06	8.9e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—GGT1—prostate cancer	8.64e-06	8.62e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—NCOA1—prostate cancer	8.51e-06	8.49e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—CYP19A1—prostate cancer	8.39e-06	8.37e-05	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—EP300—prostate cancer	8.25e-06	8.23e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—RXRA—prostate cancer	8.09e-06	8.08e-05	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—SRC—prostate cancer	8.02e-06	8e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	7.87e-06	7.86e-05	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—VEGFA—prostate cancer	7.81e-06	7.8e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—COMT—prostate cancer	7.8e-06	7.78e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—GSTP1—prostate cancer	7.76e-06	7.74e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—ITPR1—prostate cancer	7.64e-06	7.62e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—EP300—prostate cancer	7.51e-06	7.49e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—TYMS—prostate cancer	7.21e-06	7.2e-05	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—TGFB1—prostate cancer	7.17e-06	7.15e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—GSTM1—prostate cancer	7.13e-06	7.12e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—LPL—prostate cancer	7e-06	6.99e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—CYP1A1—prostate cancer	6.76e-06	6.75e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—ERCC2—prostate cancer	6.7e-06	6.69e-05	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—KRAS—prostate cancer	6.64e-06	6.63e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—MTHFR—prostate cancer	6.3e-06	6.29e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—PPARA—prostate cancer	6.18e-06	6.17e-05	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—PIK3CA—prostate cancer	6.1e-06	6.09e-05	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—TP53—prostate cancer	5.9e-06	5.89e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—CAV1—prostate cancer	5.81e-06	5.8e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	5.55e-06	5.54e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—PIK3CG—prostate cancer	5.3e-06	5.28e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—INS—prostate cancer	5.01e-06	5e-05	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—AKT1—prostate cancer	4.98e-06	4.97e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—CREBBP—prostate cancer	4.91e-06	4.9e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—PIK3CD—prostate cancer	4.65e-06	4.65e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—NOS3—prostate cancer	4.4e-06	4.39e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—PIK3CB—prostate cancer	4.06e-06	4.05e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—PTGS2—prostate cancer	4.02e-06	4.01e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—PTEN—prostate cancer	3.51e-06	3.5e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—EP300—prostate cancer	3.34e-06	3.34e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—PIK3CA—prostate cancer	2.47e-06	2.47e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—AKT1—prostate cancer	2.02e-06	2.02e-05	CbGpPWpGaD
